VRTX | tickerfilter.com

Fundamental analysis

61%

Profitability 81%

Dept financing 7%

Liquidity 75%

Performance 50%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

0.81%

1 Month

-2.67%

3 Months

-4.76%

6 Months

3.03%

1 Year

-8.03%

2 Year

9.82%

Key data

Stock price

$439.18

P/E Ratio

29.10

DAY RANGE

$437.67 - $444.01

EPS

$15.46

52 WEEK RANGE

$362.50 - $510.77

52 WEEK CHANGE

-$10.46

MARKET CAP

115.026 B

YIELD

N/A

SHARES OUTSTANDING

254.034 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

07-31-2025

BETA

1.15

PUBLIC FLOAT

AVERAGE 10 VOLUME

$1,179,421

AVERAGE 30 VOLUME

$1,251,519

Company detail

CEO: Reshma Kewalramani
Region: US
Website: vrtx.com
Employees: 4,800
IPO year: 1991

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial.

VRTX - VERTEX PHARMACEUTICALS INC / MA